celecoxib has been researched along with Glioma in 25 studies
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease." | 9.11 | Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. ( Badruddoja, M; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Vredenburgh, J, 2005) |
| "A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor)." | 7.81 | Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. ( Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J, 2015) |
| "The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model." | 7.73 | Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. ( Groves, MD; Kang, SG; Kim, JS; Nam, DH; Park, K, 2006) |
| " To determine whether oral administration of a COX-2-specific inhibitor can inhibit glial tumors, we analyzed the effect of celecoxib on the growth of 9L rat gliosarcoma cells that were orthotopically transplanted into rat brains." | 7.72 | Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. ( Eoh, W; Hong, SC; Im, YH; Kim, JH; Kim, MH; Lee, S; McDonnell, TJ; Nam, DH; Park, C; Park, K; Shin, HJ, 2004) |
| "Celecoxib has been utilized with success in the treatment of several types of cancer, including gliomas." | 5.42 | Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine. ( Winfield, LL; Yerokun, T, 2015) |
| "Gliomas are highly vascularized tumors, suggesting that the prevention of vessel formation by anti-angiogenic treatment might be effective." | 5.40 | Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. ( Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D, 2014) |
| "Malignant gliomas are heavily infiltrated by immature myeloid cells that mediate immunosuppression." | 5.40 | Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. ( Kosaka, A; Ohkuri, T; Okada, H, 2014) |
| "Malignant gliomas have low survival expectations regardless of current treatments." | 5.39 | Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib. ( Grimaldi, M; Hobrath, JV; Johnson, GG; Piazza, GA; White, MC; Zhang, W, 2013) |
| "In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease." | 5.11 | Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. ( Badruddoja, M; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Vredenburgh, J, 2005) |
| "A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor)." | 3.81 | Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. ( Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J, 2015) |
| "The selective COX-2 inhibitors NS-398, Celecoxib and Meloxicam and three human glioma cell lines (D384, U251 and U87) were used." | 3.74 | Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. ( Berg, Jv; Kuipers, GK; Lafleur, MV; Slotman, BJ; Sminia, P; Stoter, TR; Wedekind, LE, 2007) |
| "The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model." | 3.73 | Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. ( Groves, MD; Kang, SG; Kim, JS; Nam, DH; Park, K, 2006) |
| " To determine whether oral administration of a COX-2-specific inhibitor can inhibit glial tumors, we analyzed the effect of celecoxib on the growth of 9L rat gliosarcoma cells that were orthotopically transplanted into rat brains." | 3.72 | Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. ( Eoh, W; Hong, SC; Im, YH; Kim, JH; Kim, MH; Lee, S; McDonnell, TJ; Nam, DH; Park, C; Park, K; Shin, HJ, 2004) |
| "Celecoxib has been utilized with success in the treatment of several types of cancer, including gliomas." | 1.42 | Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine. ( Winfield, LL; Yerokun, T, 2015) |
| "Gliomas are highly vascularized tumors, suggesting that the prevention of vessel formation by anti-angiogenic treatment might be effective." | 1.40 | Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. ( Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D, 2014) |
| "Malignant gliomas are heavily infiltrated by immature myeloid cells that mediate immunosuppression." | 1.40 | Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. ( Kosaka, A; Ohkuri, T; Okada, H, 2014) |
| "Malignant gliomas have low survival expectations regardless of current treatments." | 1.39 | Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib. ( Grimaldi, M; Hobrath, JV; Johnson, GG; Piazza, GA; White, MC; Zhang, W, 2013) |
| "Celecoxib was incorporated into poly DL-lactide-co-glycolide (PLGA) nanoparticles for antitumor drug delivery." | 1.37 | Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells. ( Jeong, YI; Jin, SG; Jung, S; Jung, TY; Kang, SS; Kim, IY; Kim, TH; Moon, KS; Pei, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, B | 1 |
| Guo, ZS | 1 |
| Bartlett, DL | 1 |
| Yan, DZ | 1 |
| Schane, CP | 1 |
| Thomas, DL | 1 |
| Liu, J | 1 |
| McFadden, G | 1 |
| Shisler, JL | 1 |
| Roy, EJ | 1 |
| Uram, Ł | 1 |
| Markowicz, J | 1 |
| Misiorek, M | 1 |
| Filipowicz-Rachwał, A | 1 |
| Wołowiec, S | 1 |
| Wałajtys-Rode, E | 1 |
| Zhang, H | 1 |
| Tian, M | 1 |
| Xiu, C | 1 |
| Wang, Y | 1 |
| Tang, G | 1 |
| Xu, K | 2 |
| Wang, L | 1 |
| Shu, HK | 2 |
| Porkholm, M | 1 |
| Valanne, L | 2 |
| Lönnqvist, T | 2 |
| Holm, S | 1 |
| Lannering, B | 1 |
| Riikonen, P | 2 |
| Wojcik, D | 1 |
| Sehested, A | 1 |
| Clausen, N | 1 |
| Harila-Saari, A | 1 |
| Schomerus, E | 1 |
| Thorarinsdottir, HK | 1 |
| Lähteenmäki, P | 1 |
| Arola, M | 1 |
| Thomassen, H | 1 |
| Saarinen-Pihkala, UM | 2 |
| Kivivuori, SM | 2 |
| Kosaka, A | 1 |
| Ohkuri, T | 1 |
| Okada, H | 2 |
| Kerschbaumer, J | 1 |
| Schmidt, FA | 1 |
| Grams, AE | 1 |
| Nowosielski, M | 1 |
| Pinggera, D | 1 |
| Brawanski, KR | 1 |
| Petr, O | 1 |
| Thomé, C | 1 |
| Tuettenberg, J | 1 |
| Seiz, M | 1 |
| Freyschlag, CF | 1 |
| Wickström, M | 1 |
| Dyberg, C | 1 |
| Milosevic, J | 1 |
| Einvik, C | 1 |
| Calero, R | 1 |
| Sveinbjörnsson, B | 1 |
| Sandén, E | 1 |
| Darabi, A | 1 |
| Siesjö, P | 1 |
| Kool, M | 1 |
| Kogner, P | 1 |
| Baryawno, N | 1 |
| Johnsen, JI | 1 |
| Yerokun, T | 1 |
| Winfield, LL | 1 |
| Ju, RJ | 1 |
| Zeng, F | 1 |
| Liu, L | 1 |
| Mu, LM | 1 |
| Xie, HJ | 1 |
| Zhao, Y | 1 |
| Yan, Y | 1 |
| Wu, JS | 1 |
| Hu, YJ | 1 |
| Lu, WL | 1 |
| Sato, A | 1 |
| Mizobuchi, Y | 1 |
| Nakajima, K | 1 |
| Shono, K | 1 |
| Fujihara, T | 1 |
| Kageji, T | 1 |
| Kitazato, K | 1 |
| Matsuzaki, K | 1 |
| Mure, H | 1 |
| Kuwayama, K | 1 |
| Sumi, A | 1 |
| Saya, H | 1 |
| Sampetrean, O | 1 |
| Nagahirao, S | 1 |
| Kim, CK | 1 |
| Joe, YA | 1 |
| Lee, SK | 1 |
| Kim, EK | 1 |
| O, E | 1 |
| Kim, HK | 1 |
| Oh, BJ | 1 |
| Hong, SH | 1 |
| Hong, YK | 1 |
| Zhou, R | 1 |
| Zhang, LZ | 1 |
| Wang, RZ | 1 |
| Nakano, I | 1 |
| Chiocca, EA | 1 |
| Gao, H | 1 |
| Fujita, M | 1 |
| Kohanbash, G | 1 |
| Fellows-Mayle, W | 1 |
| Hamilton, RL | 1 |
| Komohara, Y | 1 |
| Decker, SA | 1 |
| Ohlfest, JR | 1 |
| Kim, TH | 1 |
| Jeong, YI | 1 |
| Jin, SG | 1 |
| Pei, J | 1 |
| Jung, TY | 1 |
| Moon, KS | 1 |
| Kim, IY | 1 |
| Kang, SS | 1 |
| Jung, S | 1 |
| White, MC | 1 |
| Johnson, GG | 1 |
| Zhang, W | 1 |
| Hobrath, JV | 1 |
| Piazza, GA | 1 |
| Grimaldi, M | 1 |
| Nam, DH | 2 |
| Park, K | 2 |
| Park, C | 1 |
| Im, YH | 1 |
| Kim, MH | 1 |
| Lee, S | 1 |
| Hong, SC | 1 |
| Shin, HJ | 1 |
| Kim, JH | 1 |
| Eoh, W | 1 |
| McDonnell, TJ | 1 |
| Reardon, DA | 1 |
| Quinn, JA | 1 |
| Vredenburgh, J | 1 |
| Rich, JN | 1 |
| Gururangan, S | 1 |
| Badruddoja, M | 1 |
| Herndon, JE | 1 |
| Dowell, JM | 1 |
| Friedman, AH | 1 |
| Friedman, HS | 1 |
| Eichele, K | 1 |
| Weinzierl, U | 1 |
| Ramer, R | 1 |
| Brune, K | 1 |
| Hinz, B | 1 |
| Kang, SG | 1 |
| Kim, JS | 2 |
| Groves, MD | 1 |
| Kesari, S | 1 |
| Schiff, D | 1 |
| Doherty, L | 1 |
| Gigas, DC | 1 |
| Batchelor, TT | 1 |
| Muzikansky, A | 1 |
| O'Neill, A | 1 |
| Drappatz, J | 1 |
| Chen-Plotkin, AS | 1 |
| Ramakrishna, N | 1 |
| Weiss, SE | 1 |
| Levy, B | 1 |
| Bradshaw, J | 1 |
| Kracher, J | 1 |
| Laforme, A | 1 |
| Black, PM | 1 |
| Folkman, J | 1 |
| Kieran, M | 1 |
| Wen, PY | 1 |
| Kuipers, GK | 1 |
| Slotman, BJ | 1 |
| Wedekind, LE | 1 |
| Stoter, TR | 1 |
| Berg, Jv | 1 |
| Sminia, P | 1 |
| Lafleur, MV | 1 |
2 trials available for celecoxib and Glioma
| Article | Year |
|---|---|
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Brain Neoplasm | 2005 |
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2007 |
23 other studies available for celecoxib and Glioma
| Article | Year |
|---|---|
Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Topics: Animals; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Combined Modality Therapy; Cyclooxygenase 2 I | 2020 |
Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Dendrime | 2020 |
Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cancer Vaccines; Celecoxib; Cell Line, T | 2013 |
COX-2 overexpression increases malignant potential of human glioma cells through Id1.
Topics: Animals; Celecoxib; Cell Line, Tumor; Cell Transformation, Neoplastic; Cyclooxygenase 2; Cyclooxygen | 2014 |
Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Case-Control Studi | 2014 |
Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD40 Antigens; Cele | 2014 |
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Che | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele | 2015 |
Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Celecoxib; Cell Lin | 2015 |
Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-Brain Barrier; Brain Neopl | 2016 |
Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cycloox | 2017 |
Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain N | 2010 |
Effect of celecoxib on proliferation, apoptosis, and survivin expression in human glioma cell line U251.
Topics: Apoptosis; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase Inhibito | 2010 |
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neop | 2011 |
Finding drugs against CD133+ glioma subpopulations.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Brain Neoplasms; Celecoxib; Combined Modality Th | 2011 |
Celecoxib can induce vascular endothelial growth factor expression and tumor angiogenesis.
Topics: Animals; Celecoxib; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2 Inhibitors; Endo | 2011 |
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
Topics: Alleles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; CD8-Positive T-Lymphocytes; Cele | 2011 |
Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells.
Topics: Acetone; Animals; Antineoplastic Agents; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement | 2011 |
Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Line, Tumor; Endoplasmic Reticulum Chaperon | 2013 |
Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Celecoxib; Cell Division; Cycloox | 2004 |
R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells.
Topics: Animals; Apoptosis; Arachidonic Acids; Blotting, Western; Brain Neoplasms; Caspase 3; Caspase 9; Cas | 2006 |
Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase | 2006 |
Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration.
Topics: Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose | 2007 |